Three-Year Results Following Microwave Therapy in Patients with Severe Primary Axillary Hyperhidrosis

TL;DR

A study shows microwave therapy (Miradry®) significantly improves symptoms and quality of life for patients with severe underarm sweating over three years.

Contribution

This paper provides long-term (three-year) evidence of microwave therapy's efficacy and safety for treating severe axillary hyperhidrosis.

Findings

Patients showed statistically significant improvement in Hyperhidrosis Disease Severity Scale (HDSS) from median 3 to 2 after three years.

Quality of life scores (HidroQoL©) improved from median 26 at baseline to 6 at three years.

Abstract

Microwave therapy (Miradry®) is an approved treatment for axillary hyperhidrosis (AH). There are several studies in the literature that show favourable safety and efficacy profile, although a few follow up patients under longer period and on larger cohort patients. In the present study, we report three-year results after microwave therapy for AH. At dermatology clinic in Östergötland 103 patients with severe AH received one or two Miradry® treatments, between 2020 and 2022. Patients were examined at several intervals during study period. Between March 2024 and June 2025, 87 patients were contacted by post and asked to complete HDSS (Hyperhidrosis Disease Severity Scale) and Hyperhidrosis Quality of Life (HidroQoL©); 45 patients have responded to our survey (response rate 51.7%). Statistically significant improvement was observed in both HDSS (from medians 3 at the study inclusion to medians 2 at 3 year) and HidroQoL© (medians 26 at baseline and medians 6 at 3 year). As a conclusion, our data demonstrate that microwave therapy is a promising long-term efficient treatment for AH and significantly improves quality of life in patients suffering from severe AH.

Level of Evidence II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

Figures